Fluad QIV (CSL) is a subunit, surface antigen-containing seasonal quadrivalent influenza vaccine adjuvanted with MF-59, an oil-in-water emulsion. It contains antigens from two A strains and two B strains specified by the World Health Organization seasonally for influenza vaccination. The vaccine was originally developed by Novartis, which divested its influenza vaccines unit to CSL in August 2015.
The vaccine is currently in Phase III development in both the US and EU. Based on CSL's plan to file for regulatory approval for elderly vaccination in the US before the end of 2019, the author expects Fluad QIV to be launched for elderly vaccination in time for the 2020/21 season.
Fluad QIV (MF-59 adjuvanted quadrivalent influenza vaccine; CSL) is the first adjuvanted quadrivalent influenza vaccine (QIV) being developed for seasonal influenza. Its superior efficacy to the standard inactivated influenza vaccines (IIVs) in the elderly is expected to boost its uptake following its anticipated launch in the 2020/21 season in the US and the 2021/22 season in the EU for the elderly.
Key Topics Covered
- Drug Overview
- Product Profiles
- Fluad QIV : Seasonal influenza vaccines
List of Tables
Table 1: Fluad QIV drug profile
Table 2: Late-phase trials of Fluad QIV for seasonal influenza vaccination
Table 3: Fluad QIV for seasonal influenza - SWOT analysis
For more information about this report visit https://www.researchandmarkets.com/r/im32l5